患有慢性病的患者的达帕格利弗洛辛和贫血
Akihiko Koshino1,2, Meir Schechter1,3,4, Glenn M Chertow5
1Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
NEJM evidence
|February 6, 2024
概括
达帕格利弗洛辛在超过一半的慢性病患者中帮助纠正贫血,并预防了新的贫血病例. 这种药物对治疗慢性病患者的贫血有前途,无论是否患有2型糖尿病.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- DAPA-CKD试验证明了达帕格利弗洛辛在慢性病 (CKD) 中对脏和心血管结果的益处.
- 贫血是CKD患者常见的并发症,影响整体健康和预后.
- 这项分析专门研究了DAPA-CKD队列中达帕格利弗洛辛对贫血的影响.
研究的目的:
- 评估达帕格利弗洛辛在治疗患有慢性结核病的患者中先前存在的贫血的疗效.
- 评估达帕格利弗洛辛 (dapagliflozin) 预防慢性病患者贫血发生的能力.
- 为了在患有或没有2型糖尿病的CKD患者中检查这些影响.
主要方法:
- 一个对DAPA-CKD试验的后期分析,涉及4304名患有CKD的患者.
- 患者接受了每天10毫克的达帕格利弗洛辛或安慰剂.
- 定期监测血红素水平,以确定贫血,其纠正和发病率.
主要成果:
- 在2.4年的中位数随访期间,达帕格利弗洛辛比安慰剂增加了2.3个百分点的血红素.
- 在接受达帕格利弗洛辛治疗的患者中,53.3%的贫血得到了纠正,而安慰剂接受者的这一比例为29.4%.
- 发生性贫血发生在10.4%的达帕格利弗洛辛患者中,而安慰剂患者中为23.7%,T2D和非T2D组的效果相似.
结论:
- 达帕格利弗洛辛 (Dapagliflozin) 与慢性病患者的贫血纠正有显著的关联.
- 达帕格利弗洛辛还在预防该人群中出现新的贫血病例方面表现出显著的效果.
- 这些发现表明,达帕格利弗洛辛可能是治疗慢性病患者贫血的一个有价值的治疗选择.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
187
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
187
Renal Failure: Dose Adjustments
89
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
89
Oral Hypoglycemic Agents: Biguanides and Glitazones
204
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
204
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Hypoglycemia and Glucagon
263
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
263
Factors Affecting Renal Clearance: Renal Impairment
95
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
95


